Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women

Conférence canadienne de consensus sur la ménopause et l’ostéoporose 2000/2001.Tiré à part du JOGC 2001; 23 (12):1–97. Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA 2002; 288:321–33. Barnabei, 2002, Menopausal symptoms in older women and the effects of treatment with hormone therapy, Obstet Gynecol, 100, 1209 Greendale, 1998, Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial, Obstet Gynecol, 92, 982 Utian, 2001, Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate, Fertil Steril, 75, 1065, 10.1016/S0015-0282(01)01791-5 Cauley, 2003, Effects of estrogen plus progestin on risk of fracture and bone mineral density—The Women's Health Initiative randomized trial, JAMA, 290, 1729, 10.1001/jama.290.13.1729 Hammar, 1998, A double-blind, randomised trial comparing the effects of Tibolone and Continuous Combined Hormone Replacement Therapy in postmenopausal women with menopausal symptoms, Br J Obstet Gynaecol, 105, 904, 10.1111/j.1471-0528.1998.tb10237.x Archer, 1994, Bleeding patterns in post-menopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate, Obstet Gynecol, 83, 686 Modelska, 2002, Tibolone for postmenopausal women: systematic review of randomized trials, J Clin Endocrinol Metab, 87, 16, 10.1210/jcem.87.1.8141 Coyle, 2003, Economic evaluation of norethisterone acetate/ethinylestradiol (FemHRT) for women with menopausal symptoms, Pharmacoeconomics, 21, 661, 10.2165/00019053-200321090-00004 Drummond F, O’Brien J, Stoddart L, Torrance W. Méthodes d’évaluation économique des programmes de santé, Deuxième Edition 1997. Pilon, 2001, Estrogen replacement therapy: determinants of persistence with treatment, Obstet Gynecol, 97, 97 Simon, 2003, A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users, Menopause, 10, 37 Huber, 2002, Effects of Tibolone and Continuous Combined Hormone Replacement Therapy on bleeding rates, quality of life and tolerability in postmenopausal women, BJOG, 109, 886, 10.1111/j.1471-0528.2002.01338.x Botteman, 2004, A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms, Menopause, 11, 343, 10.1097/01.GME.0000097742.96468.68 Plumb, 2000, Economic impact of Tibolone compared with Continuous Combined Hormone Replacement Therapy: in the management of postmenopausal women with climacteric symptoms in the UK, Pharmacoeconomics, 18, 477, 10.2165/00019053-200018050-00007 Manuel de facturation des omnipraticiens. Available at: http://www.ramq.gouv.ca/fr/professionnels/medomni/manuel/manu_tdm.shtml. Manuel de facturation des spécialistes. Available at: http://www.ramq.gouv.ca/fr/professionnels/medspe/manuel/man150.shtml. Régie de l’Assurance Maladie du Québec. Available at: http://www.ramq.gouv.qc.ca. Drug tariff online. Available at: http://www.drugtariff.com. Laupacis, 1992, How attractive does a new technology have to be to warrant adoption and utilization?, Can Med Assoc J, 146, 473 Daly, 1992, HRT: an analysis of benefits, risks and costs, Br Med Bull, 48, 368, 10.1093/oxfordjournals.bmb.a072552 Tosteson, 1991, Cost-effectiveness of Hormone Replacement Therapy after the menopause, Baillières Clin Obstet Gynaecol, 5, 943, 10.1016/S0950-3552(05)80298-6 Cheung, 1992, A cost-effectiveness analysis of Hormone Replacement Therapy in the menopause, Med J Aust, 156, 312, 10.5694/j.1326-5377.1992.tb139784.x Le Pen, 1997 Visentin, 1997, Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy, Maturitas, 26, 185, 10.1016/S0378-5122(96)01099-7 Meunier, 1999, Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines, Clin Ther, 21, 1025, 10.1016/S0149-2918(99)80022-8 Brown A, Coyle DA, Chen S, Cumming DC, Mensinkai S. Transdermal Hormone Replacement Therapy patches for women with postmenopausal symptoms: economic analysis of short-term use. CCOHTA. Technology Report 2006. Issue 61. Nathorst-Böös, 1997, Effect on sexual life-a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen, Maturitas, 26, 15, 10.1016/S0378-5122(96)01069-9 Castelo-Branco, 2000, Comparative effect of estrogens plus androgens and Tibolone on bone, lipid pattern and sexuality in postmenopausal women, Maturitas, 34, 161, 10.1016/S0378-5122(99)00096-1 Egarter, 1996, Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints, Maturitas, 23, 55, 10.1016/0378-5122(95)00953-1 Palomba, 2003, Effect of Tibolone on breast symptoms resulting from postmenopausal Hormone Replacement Therapy, Maturitas, 45, 267, 10.1016/S0378-5122(03)00153-1 Bedenek-Jaszmann, 1987, Long-term placebo-controlled efficacy and safety study of ORG OD 14 in climacteric women, Maturitas Suppl, 1, 25, 10.1016/0378-5122(87)90040-5 Walker, 1985, The effect of the synthetic steroid Org OD14 on fibrinolysis and blood lipids in postmenopausal women, Thromb Haemost, 53, 303, 10.1055/s-0038-1661302 Canadian Consensus Conference on Menopause. JOGC 2006; 28:1–93.